When was PeopleBio R&D founded?

PeopleBio R&D was founded in 2002.

Where is PeopleBio R&D located?

PeopleBio R&D is located in Seongnam-si, South Korea .

Where does PeopleBio R&D rank among its competitors?

PeopleBio R&D ranks 5 amongst 40 active competitors.

Who are the top competitors of PeopleBio R&D?

PeopleBio R&D's top competitors are Octave Bioscience, Avid and Amprion.

PeopleBio R&D - 2025 Company Profile, Funding & Competitors

PeopleBio R&D is a public company based in Seongnam-si (South Korea), founded in 2002. It operates as an Immunoassays for early detection of neuro-degenerative diseases. The company has 40 active competitors, including 14 funded and 6 that have exited. Its top competitors include companies like Octave Bioscience, Avid and Amprion.

Company Details

PeopleBio R&D is a molecular diagnostics company developing simple, reliable immunoassays for the detection of neurodegenerative diseases, such as Alzheimer's. The company's platform technology called the Multimer Detection System (MDS) is a sandwich ELISA test that uses a combination of capturing antibodies, and epitope-overlapping detection antibodies to differentiate between monomers and multimers of proteins. The assays are applicable to the detection of misfolded, oligomerized or aggregated proteins that are associated with diseases such as Alzheimer's, Parkinson's and Transmissible Spongiform Encephalopathies (such as Creutzfeldt-Jakob鈥檚 disease). The company has leveraged its MDS platform to develop tests to measure biomarkers of AD in the CSF, plasma, and exosomes, therapeutic antibodies for AD, and molecular diagnostic tests for Parkinson's disease from body fluids.

Website
Email ID: @peoplebio.net
Phone Number: +82

Key Metrics

Founded Year

2002

Location

Seongnam-si, South Korea

Stage

Public

Investors

M Venture Investment & 13 more

Ranked

5^th among

Similar Companies

Octave Bioscience &

Exit Details

Public

PeopleBio R&D is a funded company.

PeopleBio R&D has 14 institutional investors including , and .

View details of PeopleBio R&D's funding rounds and investors

Access 秘密研究所 on any website

Our Google Chrome extension lets you view company details while browsing their websites

Top competitors of PeopleBio R&D include Octave Bioscience, Avid and Amprion. Here is the list of Top 10 competitors of PeopleBio R&D, ranked by 秘密研究所 score:

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Octave Bioscience 2014, Menlo Park (United States), Series C	Provider of AI-based molecular diagnostic tools for neurodegenrative diseases	$120M	Deerfield, Casdin Capital听&补尘辫;听	55/100
2nd	Avid 2004, Philadelphia (United States), Acquired	Developer of molecular imaging agents for chronic disease diagnosis	$69.9M	Alta Partners, Lilly Ventures听&补尘辫;听	45/100
3rd	Amprion 2006, Houston (United States), Series B	Developing assay technology for neurodegenerative disorders associated with misfolded proteins	$11.8M	Lilly, HHS听&补尘辫;听	44/100
4th	ADx NeuroSciences 2011, Ghent (Belgium), Acquired	Biomarker assays for neurodegenerative diseases	$3.17M		42/100
5th	2002, Seongnam-si (South Korea), Public	Immunoassays for early detection of neuro-degenerative diseases	-	M Venture Investment, DAOL Investment听&补尘辫;听	41/100
6th	Cytox 2007, Oxford (United Kingdom), Series B	Developer for prognostic tests for assessing the risk of dementia	$12.1M	Origin Capital, Seneca EIS Portfolio Fund听&补尘辫;听	37/100
7th	Nanostics 2017, Edmonton (Canada), Seed	Developer of diagnostic tests to detect cancers, cardiovascular and neurodegenerative diseases	-		34/100
8th	Gene Solutions 2006, Charlottesville (United States), Series A	Diagnostic and therapeutic solutions for Central Nervous System diseases	$6.33M	-	27/100
9th	Durin Technologies 2010, Camden (United States), Series B	Developer of the diagnostic test for neurodegenerative diseases	$8.05M	Breakthrough Diagnostics	27/100
10th	LikeMinds 2008, Boston (United States), Series A	Provider of dopamine transporter imaging agent for diagnosis of neurodegenerative diseases	$6.37M	-	26/100